The filing is a preliminary prospectus supplement with all key terms (size, interest rate, conversion price) as placeholders. The actual terms will be set at pricing. Monitor the final prospectus supplement for the definitive offering size and conversion premium, which will determine the dilutive and leverage impact.
Price Chart
Executive Summary
Viking Therapeutics filed a preliminary prospectus supplement for an offering of convertible senior notes due 2032, with a concurrent common stock offering. The aggregate principal amount, interest rate, conversion price, and other key terms are all placeholder values (undisclosed). The filing is a capital raise to fund clinical development of VK2735 and VK3019. The stock closed at $40.85 on September 22, 2026, and the company had $125.75 million in cash as of June 30, 2026.
Key Facts
- Offering of convertible senior notes due 2032; aggregate principal amount, interest rate, and conversion price are undisclosed (placeholder values).
- Concurrent common stock offering of undisclosed size; neither offering is contingent on the other.
- Net proceeds intended for clinical development of VK2735 and VK3019 programs, plus general corporate purposes.
- As of June 30, 2026, the company had $125.75 million in cash and equivalents, no debt, and an accumulated deficit of $1.13 billion.
- On September 22, 2026, the company announced positive top-line results from the VK2735 maintenance study.
- Common stock closed at $40.85 on September 22, 2026.
Financial Impact
Undisclosed — all offering amounts are placeholder values. The company had $125.75M cash and no debt as of June 30, 2026.
Risk Factors
- Undisclosed offering size and terms create uncertainty about the magnitude of dilution and debt load.
- The concurrent common stock offering is not contingent on the note offering, so the total capital raise is uncertain.
- Proceeds will fund clinical-stage programs with no approved products, carrying inherent development and regulatory risk.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-399628 |
| Document: 0001193125-26-399628-index-headers.html | 0001193125-26-399628 |
| Document: 0001193125-26-399628-index.html | 0001193125-26-399628 |
| Document: 0001193125-26-399628.txt | 0001193125-26-399628 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | Institutional Cluster | $24.40 $24.21 | ▲ +0.78% | ▲ +1.49% | $24.89 (−2.01%) |
Oct 21, 2026 6d ago | Press Release | $25.83 $24.40 | ▼ −5.54% | ▼ −5.01% | $24.89 (−3.64%) |
Sep 28, 2026 29d ago | 8-K | $31.81 $32.60 | ▲ +2.48% | ▲ +2.69% | $24.89 (−21.75%) |
Sep 24, 2026 4w ago | 424B5 | $35.56 $33.03 | ▲ +7.11% | ▲ +6.37% | $24.89 (+30.01%) |
Sep 24, 2026 4w ago | 424B5 | $35.56 $33.03 | ▲ +7.11% | ▲ +6.37% | $24.89 (+30.01%) |
Sep 23, 2026 4w ago | 424B5 | $36.75 $35.56 | ▼ −3.24% | ▼ −3.78% | $24.89 (−32.27%) |
Sep 23, 2026 4w ago | 424B5 | $36.75 $35.56 | ▲ +3.24% | ▲ +3.78% | $24.89 (+32.27%) |
Sep 22, 2026 5w ago | 8-K | $40.85 $41.65 | ▲ +1.96% | ▲ +2.68% | $24.89 (−39.07%) |
Jul 29, 2026 12w ago | Insider Cluster | $33.11 $31.74 | ▼ −4.14% | ▼ −4.86% | $24.89 (−24.83%) |
Jul 29, 2026 12w ago | Insider Cluster | $33.11 $31.74 | ▼ −4.14% | ▼ −4.84% | $24.89 (−24.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers